CN-116773820-B - Application of insulin-like growth factor binding protein 6 as biomarker in preparation of sepsis diagnosis and treatment reagent

Abstract

The invention belongs to the technical field of biological medicines, and particularly discloses application of Insulin-like growth factor binding protein 6 (Insulin-like growth factors binding protein-6, IGFBP 6) serving as a biomarker in preparation of sepsis diagnosis and treatment reagents. The IGFBP6 can be used as a novel biological marker for assisting in diagnosing sepsis, can be used for diagnosing diseases and reflecting the severity of the diseases, can be used as a potential sepsis treatment target, and provides a novel technical means for diagnosing, prognosing and treating sepsis diseases.

Inventors

• SONG ZHIXIN
• CHEN DAPENG
• YIN YIBING
• CHEN JIE

Assignees

• 重庆医科大学附属儿童医院

Dates

Publication Date

20260512

Application Date

20230607

Claims (1)

1. Use of a STAT1 agonist and/or a macrophage chemokine for the manufacture of a medicament for the treatment and/or prevention of sepsis due to high expression of insulin-like growth factor binding protein 6, wherein the STAT1 agonist is used to increase the phosphorylation level of STAT1 and the medicament restores the macrophage recruitment ability in an organism that is impaired by the elevation of insulin-like growth factor binding protein 6 by the STAT1 agonist and/or the macrophage chemokine; the STAT1 agonist is selected from 2-NP; the macrophage chemotactic factor is selected from at least one of CCL2 and recombinant protein thereof.

Description

Application of insulin-like growth factor binding protein 6 as biomarker in preparation of sepsis diagnosis and treatment reagent Technical Field The invention relates to the technical field of biological medicines, in particular to application of insulin-like growth factor binding protein 6 serving as a biomarker in preparation of sepsis diagnosis and treatment reagents. Background Sepsis (Sepsis) is a life threatening organ dysfunction caused by host anti-infective response disorder, one of the serious complications of clinically critical patients such as wounds, burns, shock, infection, etc., and is the main cause of death for infected patients. Sepsis is usually caused by bacterial infections, but also by fungal and parasitic infections. The disease course of sepsis mainly comprises four parts, namely general infection, systemic inflammatory response syndrome, sepsis and severe sepsis, and if the sepsis is not controlled effectively in time, shock and organ failure can be caused. Because of the lack of specificity of symptoms and signs in patients with sepsis, clinical diagnosis faces a number of dilemmas, and one survey report shows that 86% of physicians consider symptoms of sepsis to be atypical, resulting in delays in diagnosis and treatment. Sometimes only about 24 hours is needed to develop from sepsis to septic shock. One retrospective cohort study investigated 2731 sepsis shock patients in 14 intensive care units and 10 hospitals in canada and the united states, and as a result found that if the patients failed to receive effective anti-infective therapy for the first 6 hours, the risk of mortality increased and the survival rate decreased by 7.6% (range 3.6% -9.9%) every 1 hour delay. Only 50% of sepsis shock patients use antibiotics within 6 h. Therefore, the improvement of the early recognition capability of clinic, the accurate evaluation of the illness state and the early implementation of reasonable treatment strategies are the problems faced by the clinicians at present. Sepsis occurs in a very complex mechanism, and is associated with a range of physiological and pathological processes such as infection, inflammation, immunity, coagulation, tissue damage, and the like. Inflammatory factors released by infection are related to various cells and systems of the whole body through a neuroendocrine immune regulation system, a huge complex network is formed, cascade effects are amplified and mutually restricted, wherein the destabilization states of the whole body inflammatory response syndrome (SIRS) and the compensatory anti-inflammatory response syndrome (CARS) caused by the imbalance of the inflammatory factors jointly promote sepsis-related immune dysfunction, the multiple organ inflammatory injury mediated by SIRS inflammation storm and the CARS-related immune suppression form a complex destabilization state, so that the treatment of sepsis is difficult to realize through simple anti-infective and anti-inflammatory drugs, and therefore, in recent years, immune new therapies based on immune regulation are attracting more and more attention, wherein the potential immune regulation effect of some key cytokines in sepsis is the focus of attention. Insulin-like growth factor binding protein 6 (Insulin-like growth factors binding protein-6, IGFBP 6) is one of the key factors which are proposed for the first time in the research of the invention and can interfere with the sepsis process, and has important significance on new strategies for diagnosis and treatment of sepsis. Disclosure of Invention In view of the above-mentioned drawbacks of the prior art, the present invention aims to provide the use of insulin-like growth factor binding protein 6 as a biomarker in the preparation of a sepsis diagnostic reagent, and the present invention discovers for the first time that IGFBP6 can be used as a novel biomarker for predictive diagnosis of sepsis, not only for diagnosis of diseases and reflecting the severity of the diseases, but also as a potential sepsis therapeutic target, and provides a novel technical means for diagnosis, prognosis and treatment of sepsis diseases. To achieve the above and other related objects, a first aspect of the present invention provides the use of insulin-like growth factor binding protein 6 as biomarker in the preparation or screening of sepsis diagnostic reagents and/or therapeutic drugs. In some embodiments of the invention, the reagent is used to determine the expression level of insulin-like growth factor binding protein 6 in a body fluid sample. In some embodiments of the invention, the level of insulin-like growth factor binding protein 6 expression in the body fluid sample is positively correlated with the severity of sepsis disease. In some embodiments of the present invention, the detection method used by the reagent is at least one selected from the group consisting of chemiluminescence, ELISA, immunoturbidimetry, immunofluorescence, and colloidal gold, but